Conversations with experts about noteworthy topics in autism.
Theofanopoulou shares how flamenco stepped up the pace of her social-communication research, and what’s behind the ‘no fear’ ethos in her new lab.
Oxytocin therapies have failed to consistently benefit autistic people, but their effects in people with two autism-linked conditions may yield new insights, experts argue.
The two psychologists share tips to help autism researchers adopt established methods and make their work more transparent and reproducible.
Researchers have long studied subgroups of people who share genetic variants, but the newly formed ‘CNV Commission’ is also looking at people with shared traits across different neurodevelopmental conditions.
When Van de Water isn’t busy mentoring “the next generation of scientists” in her lab, she finds time to paint, watch HGTV and hang out with her horse, Hank.
Shifts in diagnostic criteria have only added to the condition’s bedeviling heterogeneity, an analysis of smiling, sitting, walking and other early milestones in more than 17,000 autistic children reveals.
People’s brains have a larger network of inhibitory interneurons than mouse brains do, according to a new study. Changes to that network could contribute to autism or other conditions, says lead investigator Moritz Helmstaedter.
About 15 percent of genes currently included in clinical genetic tests for autism or intellectual disability don’t have enough evidence to support their ties to the conditions, the panel found.
People who have ‘profound autism’ — those with severe intellectual disability, limited communication abilities or both — tend to be excluded from research. The Autism Science Foundation seeks to change that.
After the vasopressin antagonist balovaptan flopped in a late-stage clinical trial, Suma Jacob and her colleagues took stock of all the factors that might have complicated the results.
